The fibrin-specific plasminogen activator – which is already sold as Metalyse and TNKase for patients with suspected acute myocardial infarction – was being tested in phase 3 stroke trials ...

highlighting the critical need for new therapies to address unmet medical needs in stroke care. While advances such as intravenous thrombolytic agents—TNKase® (tenecteplase) and Activase ...